

7321

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/028544 A1

(51) International Patent Classification⁷: A61K 31/57, 31/575, 31/58, A61P 3/06, 9/10, 25/28

(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).

(21) International Application Number: PCT/DK2003/000619

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 23 September 2003 (23.09.2003)

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data: PA 2002 01417 25 September 2002 (25.09.2002) DK

(71) Applicants (*for all designated States except US*): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). SCHERING AG [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): GRØNDAHL, Christian [DK/DK]; Irisvej 19, DK-3500 Værløse (DK). LINDENTHAL, Bernhard [DE/DE]; Wilkestrasse 19, 13507 Berlin (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/028544 A1

(54) Title: USE OF MAS-COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH LIPID METABOLISM

(57) Abstract: Certain sterols can be used for increasing the HDL cholesterol to non-HDL cholesterol ratio, for treatment and/or prevention of atherosclerosis, for treatment and/or prevention of hyper-lipidemia, for treatment of diabetic dyslipidemia, for treatment of hyper-cholesterolemia, for treatment of diseases of illness related to metabolic dysfunction, for treatment of obesity or obesitas related diseases, and for the treatment of neurological diseases.

USE OF MAS-COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH LIPID METABOLISM

FIELD OF THE INVENTION

5 This invention relates to the use of novel compounds mentioned below for increasing the HDL cholesterol to non-HDL cholesterol ratio, for treatment and/or prevention of arteriosclerosis, for treatment and/or prevention of hyperlipidemia, for treatment of diabetic dyslipidemia, for treatment of hyper-cholesterolemia, for treatment of diseases of illness related to metabolic dysfunction, for treatment of obesity or obesitas related diseases, and for treatment of neurological diseases, for example, Alzheimer, associated with lipid metabolism.
10 The present invention also embraces pharmaceutical compositions and kits comprising these compounds and methods of using the compounds and their pharmaceutical compositions, for example, to humans.

BACKGROUND OF THE INVENTION

15 Herein the term lipoprotein covers any of the lipid-protein complexes in which lipids are transported in the blood. Lipoprotein particles consists of a spherical hydrophobic core of triglycerides or cholesteryl esters surrounded by an amphiphatic monolayer of phospholipids, cholesterol, and apolipoproteins. The expression HDL cholesterol covers high-density lipoprotein and the expression non-HDL cholesterol covers the remaining lipoproteins.

20 Atherosclerosis is an extremely common form of arteriosclerosis in which deposits of yellowish plaques (atheromas) containing cholesterol, lipid material, and lipophages are formed within the intima and inner media of large and medium-sized arteries. Arteriosclerosis is a group of diseases characterized in thickening and loss of elasticity of arterial walls.

Hyperlipidemia is a general term for elevated concentrations of any or all of the lipids in the plasma, including, for example, hypertriglyceridemia and hypercholesterolemia.

Diabetic dyslipidemia is the typical lipid disorder associated to type II diabetes characterized by low HDC, high LDC, and high small very dense lipid particles.

Hyper-cholesterolemia is the presence of an excess of cholesterol in the blood.

30 Metabolic dysfunctions cover the general term describing an inappropriate regulation of the glucose and lipid metabolism.

Alzheimer's disease is a progressive degenerative disease of the brain of unknown etiology characterized by diffuse atrophy throughout the cerebral cortex with distinctive histopathology changes termed "senile plaques" (microscopic lesions composed of fragmented

axon terminals and dendrites surrounding a core of amyloid) and "neurofibrillary tangles" (intracellular knots or clumps of neurofibrils).

5 In many countries, obesity is becoming a steadily increasing problem. Great effort has been devoted to this problem and the elevated health risk associated with obesity and metabolic imbalance. For example, over weighty people have an increased risk of developing diabetes. For several subgroups of the population, for example, diabetics, overweight increases the risks in connection with the parent disease. Recent research also revealed connections between cholesterol metabolism and diseases of the central nervous system. For example, it
10 is possible to delaying or preventing the onset of Alzheimer disease by cholesterol synthesis inhibitors. Large portions of the health care budgets are nowadays used in obesity or obesity related fields.

Many steps in the cholesterol synthesis are known. For example, the cholesterol synthesis
15 proceeds via the following compounds: HMG-CoA → evalonic acid → lanosterol → FF-MAS → T-MAS → desmosterol → cholesterol. Several statins, for example, Simvastatin, are known to interact on the HMG-CoA → evalonic acid step. The desmosterol → cholesterol is controlled by a sterol Δ^{24} reductase.

20 One object of this invention is to provide a medicament which can be used for increasing the HDL cholesterol to non-HDL cholesterol ratio.

Another object of this invention is to provide a medicament which can be used for treatment and/or prevention of arteriosclerosis.

25 A further object of this invention is to provide a medicament which can be used for treatment and/or prevention of hyperlipidemia.

A still further object of this invention is to provide a medicament which can be used for treatment of diabetic dyslipidemia.

A still further object of this invention is to provide a medicament which can be used for treatment of hyper-cholesterolemia.

30 A still further object of this invention is to provide a medicament which can be used for treatment of diseases of illness related to metabolic dysfunction.

A still further object of this invention is to provide a medicament which can be used for treatment of obesity or obesitas related diseases.

35 A still further object of this invention is to provide a medicament which can be used for treatment of neurological diseases, e. g. Alzheimer disease.

Other objects of the present invention will become apparent upon reading the present description.

DEFINITIONS

5

Herein, FF-MAS is 4,4-dimethyl-5 α -cholesta-8,14,24-triene-3 β -ol, T-MAS is 4,4-dimethyl-5 α -cholesta-8,24-diene-3 β -ol (also designated 4,4-dimethylzymosterol), and ZK 255884 is (20S)-20-[(piperidin-1-yl)methyl]-4,4-dimethyl-5 α -pregna-8,14-dien-3 β -ol (compound No. 2 in the list below).


10

DESCRIPTION OF THE INVENTION

It has now, surprisingly been found that certain compounds hereinafter designated MAS compound which are defined below can be used for increasing the HDL cholesterol to non-
15 HDL cholesterol ratio, for treatment and/or prevention of atherosclerosis, for treatment and/or prevention of hyperlipidemia, for treatment of diabetic dyslipidemia, for treatment of hyper-cholesterolemia, for treatment of diseases of illness related to metabolic dysfunction, and for treatment of obesity or obesitas related diseases.


20 Herein MAS compounds are all compounds of the general formula I, Ia, Ib, and Ic mentioned in any of the international patent applications having the international publication number WO 96/00235 (our ref.: 4228), WO 97/00884 (our ref.: 4475), WO 98/28323 (our ref.: 5141), WO 99/32506 (earliest priority: 971218), WO 98/52965 (earliest priority: 970516), WO 99/67273 (our ref.: 5558), WO 99/58549 (our ref.: 5509), or WO 2000/47604 (our ref.: 5769), WO
25 2000/68245 (our ref.: 6238), or WO 2001/62771 (our ref.: 6239), preferably all the specific compounds mentioned specifically in said WO specifications covered by said formula, as well as compounds of the general formula X shown below:

4



X

wherein in the moiety of the following formula



XA

- each bond between C⁵ and C⁶, between C⁸ and C⁷, between C⁷ and C⁸, between C⁸ and C⁹,
 5 between C⁸ and C¹⁴ and between C¹⁴ and C¹⁵, independently, is a single bond or a double bond, at least one of these bonds being a double bond, and wherein each carbon atom C⁵, C⁶, C⁷, C⁸, C⁹, C¹⁴ and C¹⁵ is bonded to each neighbouring C atom by a single bond or at the most by one double bond, and wherein between all other carbon atoms of the steroid skeleton are single bonds, and C³R³ is a) C³=O or b) C³H-OR^{3'}, wherein R^{3'} is selected from the
 10 group, comprising hydrogen, unsubstituted or substituted, linear or branched C₁ - C₁₀ alkyl and C³(O)-R^{3''}, bonded to the CH-O moiety via the C(O) moiety, wherein R^{3''} is selected from the group, comprising i) substituted or unsubstituted, linear or branched C₁ - C₁₀ alkyl, ii) substituted or unsubstituted, linear or branched C₁ - C₁₀ fluoro alkyl, iii) unsubstituted or substituted C₆ - C₁₀ aryl, iv) unsubstituted or substituted C₅ - C₁₀ heteroaryl, v) unsubstituted or
 15 substituted, linear or branched C₁ - C₁₀ alkyloxy and vi) unsubstituted or substituted, linear or branched C₁ - C₁₀ alkylamino, or c) C³H-SO₂-R^{3'''} or C³=NOR^{3'''}, wherein R^{3'''} has the same meaning as above, or d) C³H-O-R^{3'''}, wherein R^{3'''} is unsubstituted or substituted, linear or branched C₂ - C₁₀ alkylene and forms a cyclic ether both with the C atom of the steroid skeleton and the O atom, or e) a cyclic ring structure with the C³ atom, wherein R³ is unsubstituted
 20 or substituted, linear or branched C₂ - C₁₀ alkylene, or f) C³H-Hal, wherein Hal is F, Cl, Br or I,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.